Article
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Cancer research communications - 22 Feb 2024
Goldberg Jonathan, Qiao Na, Guerriero Jennifer L, Gross Brett, Meneksedag Yagiz, Lu Yoshimi F, Philips Anne V, Rahman Tasnim, Meric-Bernstam Funda, Roszik Jason, Chen Ken, Jeselsohn Rinath, Tolaney Sara M, Peoples George E, Alatrash Gheath, Mittendorf Elizabeth A
Abstract excerpt
Estrogen receptor-positive (ER+) breast cancer is not considered immunogenic and, to date, has been proven resistant to immunotherapy. Endocrine therapy remains the cornerstone of treatment for ER+ breast cancers. However, constitutively activating mutations in the estrogen receptor alpha (ESR1) gene can emerge during treatment, rendering tumors resistant to endocrine therapy. Although these mutations represent a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.